Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit

27 Apr 2020

Abstract excerpt

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a poor prognosis and limited therapeutic options. Alpha-fetoprotein (AFP), an established clinical biomarker of HCC, has been employed as an attractive target for T cell-based immunotherapy against this disease given its high expression in the tumor and restricted expression in normal tissues. We have identified a number of T cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32425926
DOI: 10.3389/fimmu.2020.00623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and BenefitPMID 32425926Read ↗

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinomaSemantic proximity Read ↗

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.Semantic proximity Read ↗

A systematic safety pipeline for selection of T-cell receptors to enter clinical useSemantic proximity Read ↗

Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4(+) T cells.Semantic proximity Read ↗

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity RiskSemantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma.Semantic proximity Read ↗

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinomaSemantic proximity Read ↗

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read ↗

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read ↗

Targeting hepatocellular carcinoma with aptamers: from biomarker detection to therapeutic applicationsSemantic proximity Read ↗

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.